Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| GHK (without copper) | KPV | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 1-3% concentration in topical formulations. Injectable dosing follows GHK-Cu protocols at 1-2 mg daily. | Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation. |
| Timing | Topical application morning and evening. Injectable in evening. | Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous. |
| Cycle Duration | Topical use can be ongoing indefinitely. Injectable cycles 8-12 weeks. | 4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide found in human plasma, saliva, and urine that has an extremely high affinity for copper(II) ions. Even without exogenously complexed copper, GHK rapidly chelates available copper in biological systems, making copper-free GHK functionally similar to GHK-Cu in vivo. The peptide stimulates collagen and glycosaminoglycan synthesis, modulates metalloproteinase activity, resets gene expression patterns toward a healthier state (affecting 31.2% of human genes), and activates wound healing cascades.
Research indicates 1-3% concentration in topical formulations. Injectable dosing follows GHK-Cu protocols at 1-2 mg daily.
Topical application morning and evening. Injectable in evening.
Topical use can be ongoing indefinitely. Injectable cycles 8-12 weeks.
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) that inhibits NF-kB signaling through a non-melanocortin receptor-mediated mechanism. It is transported intracellularly via the PepT1 transporter, where it stabilizes IkB-alpha and suppresses nuclear translocation of p65RelA by competing with importin-beta at the armadillo domain 7 and 8 binding site. It also reduces MAPK inflammatory signaling and IL-8 secretion in intestinal epithelial cells.
Research indicates 200-500 mcg daily via subcutaneous injection, or 500 mcg-1 mg orally for gut-targeted inflammation.
Oral dosing on empty stomach for gut-targeted effects. No strict timing for subcutaneous.
4-12 weeks. Oral protocols for gut inflammation may extend longer under supervision.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →